Agenus subsidiary amends Ocean 1181 loan, extends maturity to 2029
Agenus West and Agenus Inc. restructured a $24.75 million promissory note with lender Ocean 1181 LLC, pushing the maturity date back roughly three years.
SEC filing
Latest
6 stories
Tuesday, August 18
Wednesday, August 12
Agenus grants CEO Garo Armen a special performance stock option award
Agenus's Compensation Committee approved a one-time award of nearly 2 million performance-based options for Chairman and CEO Garo Armen, priced above market to match his team's terms.
SEC filing (2)
Tuesday, August 11
Agenus posts results for zalifrelimab plus balstilimab trial in advanced cervical cancer
Thursday, August 6
Agenus advances Phase 3 ROBBIN trial in colon cancer, backed by July financing
Agenus reported second-quarter 2026 results and said dosing in its planned Phase 3 ROBBIN trial is expected to begin in early 2027, supported by a private placement completed in July.
SEC filing
Thursday, July 30
Dana-Farber registers Phase 2 trial of Agenus drugs in early rectal cancer
Monday, July 13
Agenus secures up to $340 million to fund Phase 3 ROBBIN trial in MSS colon cancer
The private placement includes $85 million upfront and up to $255 million in warrant proceeds, while Agenus drops funding for its BATTMAN trial in late-line disease.
SEC filing